Orexo AB
http://www.orexo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orexo AB
US IPO Market In 2022 Even Underperformed Normal Years
INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out a positive average return, however.
Nasal Naloxone On Brink Of OTC Among Additional Opioid Overdose Options On US FDA's Plate
Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids.
More Options For Opioid Overdose: Nasal Naloxone On Brink Of OTC Use, While Opiant And Orexo Stay Rx To Counter High-Potency Opioids
Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids.
Towa Profits Take 87% Nosedive In Face Of Increased Costs
Japanese generics firm Towa has seen its profits slashed as increased expenses stemming from its acquisition of Sunsho Pharmaceutical decimated its bottom line in Q3.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Biolipox AB
- PharmaKodex Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice